Patent · US Active

VEGF antagonist formulations suitable for intravitreal administration

US11084865B2 · kind B2 · utility

13Cited by

9References

64Claims

0Family size

Assignee

REGENERON PHARMACEUTICALS, INC. · US

Inventors

Eric Furfine · Concord, US
Daniel Dix · Lagrangeville, US
Kenneth S. Graham · Pleasant Valley, US
Kelly Frye · Mendham, US

Key dates

Filing date	Jan 10, 2020
Grant date	Aug 10, 2021
Priority date	—
Expiry date	Jan 10, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.